PROTOCOL SPECIFIC RESERACH SUPPORT

$128,252P30FY2012CANIH

Fred Hutchinson Cancer Research Center, Seattle WA

Investigators

Linked publications & trials

Paper 39763863 Paper 39713455 Paper 39609400 Paper 39606455 Paper 39606437 Paper 39605726 Paper 39604364 Paper 39553986 Paper 39535893 Paper 39526730 Paper 39516665 Paper 39494040 Paper 39463992 Paper 39450393 Paper 39401968 Paper 39391570 Paper 39386474 Paper 39386455 Paper 39377586 Paper 39371366 Paper 39368130 Paper 39365700 Paper 39361354 Paper 39331659 Paper 39315814 Paper 39294453 Paper 39282444 Paper 39257755 Paper 39240111 Paper 39233917 Paper 39210036 Paper 39195559 Paper 39179107 Paper 39174756 Paper 39169114 Paper 39163616 Paper 39161959 Paper 39150991 Paper 39141346 Paper 39133650 Paper 39133444 Paper 39127048 Paper 39121442 Paper 39112630 Paper 39108240 Paper 39104770 Paper 39102335 Paper 39095638 Paper 39091804 Paper 39071291 Paper 39069136 Paper 39053946 Paper 39052387 Paper 39032493 Paper 39026837 Paper 39018351 Paper 39017661 Paper 39005399 Paper 39005354 Paper 39001544 Paper 39001542 Paper 38979380 Paper 38978570 Paper 38961298 Paper 38955177 Paper 38953655 Paper 38926438 Paper 38924728 Paper 38918394 Paper 38915666 Paper 38914227 Paper 38908483 Paper 38900833 Paper 38890069 Paper 38879699 Paper 38876098 Paper 38874345 Paper 38870441 Paper 38867349 Paper 38856693 Paper 38854108 Paper 38853984 Paper 38830960 Paper 38826197 Paper 38815238 Paper 38814624 Paper 38806464 Paper 38801746 Paper 38786753 Paper 38785459 Paper 38760413 Paper 38748774 Paper 38747505 Paper 38746248 Paper 38740820 Paper 38728140 Paper 38712102 Paper 38710906 Paper 38703776 Paper 38683966

Abstract

The Protocol-Specific Research Support program is coordinated within the Research Trials Office, and provides funding for dedicated research nurse and data manager support for the coordination and implementation of important early, innovative, proof-of-principle clinical trials initiated by Consortium investigators. The availability of research nurses and data coordinators with specialized expertise in these complex trials will be critical to launching the Consortium's Phase I novel therapeutics program.

View original record on NIH RePORTER →